A phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype - the P[R]EBEN study

Trial Profile

A phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in CD-20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype - the P[R]EBEN study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 May 2017

At a glance

  • Drugs Pixantrone (Primary) ; Rituximab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PREBEN
  • Most Recent Events

    • 06 Dec 2016 Results(n=30) assessing preliminary clinical experience presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (2016).
    • 07 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top